Fusion of SARS-CoV-2 neutralizing LCB1 peptide with Bacillus amyloliquefaciens RNase improves antiviral efficacy

Fusion of SARS-CoV-2 neutralizing LCB1 peptide with Bacillus amyloliquefaciens RNase improves antiviral efficacy

Abstract Virus-neutralizing peptides (VNPs) emerged as promising antiviral drug candidates with unprecedented specificity and cost-effectiveness during the recent COVID-19 pandemic. However, limited avidity, lack of effector functions, short circulatory half-life, and restricted administration route...

Full description

Saved in:
Bibliographic Details
Main Authors: Nikita N. Kostin, Tatyana V. Bobik, Elena V. Konovalova, Milita V. Kocharovskaya, Maria A. Simonova, Natalia Yu Rushkevich, Yuliana A. Mokrushina, George A. Skryabin, Roman S. Kalinin, Sergey I. Kovalchuk, Rustam H. Ziganshin, Leonid A. Kaluzhskiy, Oksana V. Gnedenko, Evgeniy O. Yablokov, Alexis S. Ivanov, Aleksandr S. Chernov, Vitaly A. Kazakov, Oksana N. Khokhlova, Arkady N. Murashev, Senlian Hong, Elena I. Shramova, Alexey A. Schulga, Ekaterina N. Lyukmanova, Mikhail P. Kirpichnikov, Ivan V. Smirnov, Alexey A. Belogurov, Yuri P. Rubtsov, Alexey V. Stepanov, Hongkai Zhang, Alexander G. Gabibov, Sergey M. Deyev
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Antiviral peptide
Half-life extension
Pharmacokinetics
Virus neutralizing peptides (VNPs)
Barnase
SARS-CoV-2
Online Access:https://doi.org/10.1038/s41598-025-12444-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-12444-2

Similar Items